R
Rehan Akbani
Researcher at University of Texas MD Anderson Cancer Center
Publications - 134
Citations - 106557
Rehan Akbani is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Gene & Cancer. The author has an hindex of 65, co-authored 124 publications receiving 84443 citations. Previous affiliations of Rehan Akbani include University of Texas at San Antonio & National Institutes of Health.
Papers
More filters
Journal ArticleDOI
Enhancing role-based trust management with a reputation system for MANETs
Rehan Akbani,Turgay Korkmaz +1 more
TL;DR: This work starts with role-based trust management (RBTM) and addresses some of the challenges associated with using RBTM in mobile ad hoc networks (MANETs), enhances RBTM with reputation systems (RSs), and proposes a new hybrid trust management system (HTMS).
Book ChapterDOI
Analytical Platforms 3: Processing Samples via the RPPA Pipeline to Generate Large-Scale Data for Clinical Studies.
TL;DR: RPPA Core processes associated with theRPPA Pipeline workflow from sample receipt to sample printing to slide staining and RPPA report generation that enables the RPPA Core to process at least 13,000 samples per year with approximately 450 individual RPPA-quality antibodies are covered.
Journal ArticleDOI
Comprehensive molecular characterization and analysis of muscle-invasive urothelial carcinomas.
Seth P. Lerner,Gordon Robertson,Jaegil Kim,Andrew D. Cherniack,Guangwu Guo,Rehan Akbani,Rupa S. Kanchi,Katherine A. Hoadley,Toshinori Hinoue,Peter W. Laird,Hikmat Al-Ahmadie,Joaquim Bellmunt,Mauro A. A. Castro,Dmitry A. Gordenin,Gordon B. Mills,Francisco Sanchez-Vega,Sachet A. Shukla,Ewan A. Gibb,John N. Weinstein,David J. Kwiatkowski +19 more
TL;DR: The entire cohort of 412 tumors from the TCGA project in chemotherapy-naive, muscle-invasive urothelial bladder cancer is reported on, with a high overall somatic mutation rate and APOBEC mutagenesis explained 70% of the mutation burden and was associated with survival.
Journal ArticleDOI
The Cancer Genome Atlas Project on Muscle-invasive Bladder Cancer.
Seth P. Lerner,John N. Weinstein,David J. Kwiatkowski,David J. Kwiatkowski,Jaegil Kim,Gordon Robertson,Katherine A. Hoadley,Rehan Akbani,Chad J. Creighton +8 more
TL;DR: The Cancer Genome Atlas project in bladder cancer reported the integrated genomic analysis of the first 131 patients in 2014, and this muscle-invasive cohort was found to have one of the highest somatic mutation rates.
Journal ArticleDOI
Whole-genome characterization of lung adenocarcinomas lacking alterations in the RTK/RAS/RAF pathway.
Jian Carrot-Zhang,Jian Carrot-Zhang,Xiaotong Yao,Siddhartha Devarakonda,Aditya Deshpande,Jeffrey S. Damrauer,Tiago C. Silva,Christopher K. Wong,Hyo Young Choi,Ina Felau,A. Gordon Robertson,Mauro A. A. Castro,Lisui Bao,Esther Rheinbay,Esther Rheinbay,Eric Minwei Liu,Tuan Trieu,David Haan,Christina Yau,Christina Yau,Toshinori Hinoue,Yuexin Liu,Ofer Shapira,Kiran Kumar,Kiran Kumar,Karen Mungall,Hailei Zhang,June Koo Lee,Ashton C. Berger,Galen F. Gao,Binyamin Zhitomirsky,Binyamin Zhitomirsky,Wen-Wei Liang,Meng Zhou,Meng Zhou,Sitapriya Moorthi,Alice H. Berger,Eric A. Collisson,Michael C. Zody,Li Ding,Andrew D. Cherniack,Andrew D. Cherniack,Gad Getz,Gad Getz,Olivier Elemento,Christopher C. Benz,Josh Stuart,Jean C. Zenklusen,Rameen Beroukhim,Rameen Beroukhim,Rameen Beroukhim,Jason C. Chang,Joshua D. Campbell,D. Neil Hayes,Lixing Yang,Peter W. Laird,John N. Weinstein,David J. Kwiatkowski,Ming-Sound Tsao,William D. Travis,Ekta Khurana,Benjamin P. Berman,Benjamin P. Berman,Katherine A. Hoadley,Nicolas Robine,Kanika Arora,Minita Shah,Jennifer Shelton,Reanne Bowlby,Verena Friedl,Mary Goldman,Brian Craft,David I. Heiman,Iman Hajirasouliha,Camir Ricketts,Pavana Anur,Kami E. Chiotti,Samantha J. Caesar-Johnson,John A. Demchok,Martin L. Ferguson,Anab Kemal,Roy Tarnuzzer,Zhining Wang,Liming Yang,Paul T. Spellman,Benjamin J. Raphael,Rehan Akbani,Jingchun Zhu,Steven J.M. Jones,Hui Shen,Matthew Meyerson,Matthew Meyerson,Ramaswamy Govindan,Marcin Imielinski +93 more
TL;DR: In this paper, the authors used whole-genome sequencing (WGS) of 85 cases found to be RPA(−) by previous studies from The Cancer Genome Atlas (TCGA) to characterize the minority of lung adenocarcinoma (LUAD) lacking apparent alterations in this pathway.